29 November 2017: The BioHub Birmingham®, which provides flexible laboratory space for pre-revenue life science companies, has announced its expansion to meet the growing demand for laboratory space in the Midlands. When the University-owned BioHub building first opened in 2015, its ground floor was designed and fully fitted out to be a shared-space life science incubator. By early 2016, the ground floor had reached capacity, had a waiting list of interested tenants and was fielding enquiries from existing tenants about grow-on space. The resident companies thrived as a result of being part of Birmingham’s integrated life sciences ecosystem, which includes 550 medical companies, over 180 medical organisations, 80 hospitals and specialist care centres, 44 GP clinics and routine care facilities, and 23 training facilities. “Birmingham is increasingly visible as a destination for early stage medical and life science companies”, says Dr James Wilkie, CEO of the Birmingham Research Park, which hosts the BioHub Birmingham®. “In the last months alone, we had more than 10 enquiries from overseas companies who are looking seriously at Birmingham as the location for their UK operations.” The life science sector will be in the first wave of sector deals highlighted in the Industrial Strategy White Paper, and is one of many sectors in which Birmingham is poised to reap benefits. The University is investing £606 million investment in infrastructure to build assets that will further bring together the clinical, academic and commercial strengths of the region, and make Birmingham a destination of choice for life science companies. The first floor of the BioHub will be fitted out to offer life science companies their own self-contained laboratory spaces, with adjacent office and breakout space. Companies on the site will also benefit from access to the world-class research of the University of Birmingham and other business support services. This type of life science incubator space is widely available and selling strongly elsewhere in the UK yet there is no similar offering within Birmingham, and several potential tenants have already expressed interest. The development will start in early 2018, and complete within the year. ENDS For further information contact Ruth Ashton, Reputation and Communications Development Manager, firstname.lastname@example.org, or tel 0121 414 9090 (out of hours 07989 558041). About the BioHub Birmingham® The BioHub hosts a thriving community of researchers and early stage life science companies including Linear Diagnostics, Nonacus, Gifford Bioscience and Future Genetics. For more information about the BioHub Birmingham®, see www.thebiohub.co.uk. About the life sciences ecosystem in Birmingham The Edgbaston Medical Quarter hosts 64% of the city’s healthcare economy and is home to 550 medical companies, over 180 medical organisations, 80 hospitals and specialist care centres, 44 GP clinics and routine care facilities, and 23 training facilities. In addition to the expertise, the medical assets that are embedded in and around the University are particularly attractive to overseas companies. Birmingham Health Partners facilitate industry collaborations with the NHS and are dedicated to speeding up development from bench to bedside. About the University of Birmingham The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 5,000 international students from over 150 countries.
A road surface temperature sensor developed at the University of Birmingham, which provides real-time data on road surface conditions, is set for rapid adoption on the UK’s road and motorway network following a national award at the Highways UK 2017 Intelligent Infrastructure Challenge. Lee Chapman, Professor of Climate Resilience at the University won the national award for a low-cost, non-invasive and self-contained road surface temperature sensor which remotely senses road surface temperature using infrared themometry. The Wintersense sensors are Internet of Things enabled, and use a new generation of low power communications to provide a real-time measurement of road surface temperature, that will be used to direct gritting lorries to priority areas. The judging panel included representatives from Highways England, Transport Scotland, England’s Economic Heartland and Transport for the North (TfN). The judges felt that deploying this type of sensor network could have an immediate impact on their ability to better control gritting routines in winter. Throughout the winter months, highways maintenance companies dispatch fleets of gritting lorries to prevent or mitigate the impact of black ice formation on motorways and A roads. In harsh winters, the routing of gritting lorries has to be prioritised to ensure optimal road safety. The University of Birmingham is an institution that has a long history of research into winter road sensing and forecasting. Lee Chapman commented: “The key issue in this prioritisation is having good spatial resolution on observation of road surface conditions. Our sensors are an order of magnitude cheaper than existing solutions, and light enough to be mounted on any lamp post, gantry or road sign, which means a dense network of sensors can be rapidly deployed along a road network to provide a highly granular picture of road surface conditions.” The Wintersense sensors are part of a portfolio of products that provide decision-making tools to empower transport managers in the road maintenance and rail industries.
Indian biotech leaders visit Birmingham for life science facilities briefing A delegation of Indian biotech company leaders visited the University of Birmingham to see the life sciences cluster, where the University’s world-leading research is translated into new medical therapies. The delegation travelled to Birmingham as part of bioConclave 2017 - an annual gathering of Indian life science business leaders, who come to the UK to explore investment and partnership opportunities. Birmingham’s life science ecosystem combines basic research and translational facilities in a single site, and is rapidly becoming a major site for health research investment. The visitors were welcomed by Indian Consul General Dr Aman Puri, West Midlands Mayor Andy Street, and Dr James Wilkie, CEO, University of Birmingham Enterprise, which runs business incubation and commercialisation services for the University. They toured the University’s Institute of Translational Medicine, the biobank, the gene and cell therapy manufacturing facility, the Queen Elizabeth Hospital, the School of Dentistry and the BioHub and BizzInn incubation facilities. Professor Robin Mason, Pro-Vice Chancellor (International), said: “The University of Birmingham has a long-standing strength in life sciences. Four of our 11 Nobel Prize winners received their awards for work revealing the structure of DNA; developing new treatments for heart disease and cancer; understanding pain relief; and pioneering organ transplants. “Birmingham is one of the UK’s most important sites for life sciences - characterised by strong partnerships that link academic excellence with innovation in addressing the health care requirements of a diverse regional population of five million people. “The University’s engagement in India is extensive, dating back to 1909 when we welcomed our first students from India to our Edgbaston campus. For both these reasons, we are very pleased to be hosting this delegation visit as part of bioConclave 2017.” Dr James Wilkie said: “Birmingham has a long established ecosystem that accelerates innovations in medicine. Our clinical-academic partnerships support all stages of the journey from bench studies to clinical trials and post-marketing surveillance studies. “Our resources, such as the Birmingham BioHub, the UK’s first dedicated shared facility for early stage life science companies, are co-located in close proximity to the University of Birmingham and two of the largest Hospitals in the country – this speeds up the translation of research, enables more rapid assessment, and quicker adoption of medical technologies.” Naveen Kulkarni, CEO of Quantumzyne, is a senior delegate from the Association of Biotech Led Enterprises – the pan-India forum representing the Indian biotechnology sector. He said: “The UK market is a global innovation hub for biotechnology and has a world-class pharmaceutical industry. The potential for UK-India collaborations in life sciences and biotech could see UK biotechs and pharma companies leverage innovative technology and market access to India.” This year’s bioConclave saw the main one-day conference programme held in London, before delegates travelled to Birmingham to learn more about the University’s research and incubation facilities and opportunities in the city. Dr Aman Puri, Consul General of India, said: “I am delighted to attend bioConclave 2017. Collectively, we should explore opportunities for greater collaboration between British institutes of excellence such as Birmingham BioHub and India's Genome Valley, where six out of 10 world leaders in biotech R&D already have a presence. “Britain is a global innovation hub, and must increase its footprint in India – an economy which is the fastest growing large economy of the world. The pharma market is projected to grow to US$ 55 billion by 2020 making it the sixth largest market in the world and the biotechnology market is likely to grow to US$ 100 billion by 2025. “After the US, India is the second largest producer of English-speaking highly skilled scientific and technical human resources, a critical component for advancement in these sectors.” India remains one of the largest foreign investors into the UK, with biotech, pharma and life sciences investments creating or safeguarding 7,049 jobs in the UK, according to the latest figures from the Department for International Trade. For more information or interviews, please contact Tony Moran, International Communications Manager, University of Birmingham on +44 (0) 121 414 8254 or +44 (0)782 783 2312. For out-of-hours enquiries, please call +44 (0) 7789 921 165.
Rainbow Seed Fund & University of Birmingham Back Promising Technology Spinout Linear Diagnostics
Spinout developing novel hand-held reader to help in the fight against antibiotic resistance
Birmingham, UK (PRWEB UK) 24 May 2017 - Rainbow Seed Fund, an early-stage venture capital fund focused on building technology companies from the UK's research base, announced today an investment into University of Birmingham spinout Linear Diagnostics. The investment was match-funded with an award from the University of Birmingham’s Spinout Investment fund and the company received a total investment of £300,000.
The investment will enable Linear Diagnostics to develop its platform technology into a handheld device that can rapidly detect the presence of bacterial infection and simultaneously identify the risk of resistance to the most commonly prescribed antibiotics, without the need for laboratory facilities. The device will provide a readout within minutes of sampling.
INNOVATION EVENT TO SHOWCASE THE SUPPORT YOU NEED, WHATEVER YOUR BUSINESSVenturefest West Midlands, the event for entrepreneurship, innovation and investors, will arrive back at the NEC in Birmingham on the 27th June and this year with the increased support of Barclays Bank, who will be offering even more support and expert advice to help to early stage entrepreneurs and established business owners grow their business. Venturefest is a free, one-day event aimed at supporting business growth through innovation. It will bring together entrepreneurs, innovators and investors, bringing with it a wealth of opportunity to network with fellow entrepreneurs and local support providers.
Smart Antenna Technologies (SAT) is opening a research facility in the Taiwanese capital of Taipei.The company, set up 2013, will initially hire five new engineers to work with customers in China, Japan and Taiwan. SAT currently employs 19 engineers and researchers at its Birmingham HQ and at a separate office in Bath. The Taiwanese facility will be managed from the Edgbaston headquarters. Currently smartphones and laptops have up to five separate antennas for Bluetooth, WiFi and 4G connections. SAT’s technology enables a device’s multiple antennae to be sited in one unit. SAT’s technology can also extend device battery life by up to 10%.
Rightangled Diagnostics was one of six UK companies chosen to take part in a trade mission to Texas to showcase UK healthcare excellence. The trade visit was organised by the Association of British Healthcare Industries (ABHI) and was supported by the UK government.
We held a vibrant BioBrum 2017 last week at the Birmingham Research Park. The first national event of its kind hosted by The BioHub Birmingham was a great success with lively networking, talks packed with useful content and personal insights from entrepreneurial journeys. We were delighted to present the prize of six months free laboratory space at The BioHub Birmingham and business support to our winner - Linear Diagnostics.
We are delighted to welcome Intray Limited to The BioHub Birmingham.
The BioHub Birmingham® hosts national life science event.The BioHub Birmingham®, Birmingham’s flagship life science incubator, is hosting its first BioBrum Life Science event on 16th February 2017. Aimed at pre-revenue life science companies the free event will include talks on finance, intellectual property, effective use of professional networks and business development. There will also be an opportunity for one-to-one advice sessions with IP, finance and business planning specialists. The event will be held at the Birmingham Research Park, which houses a community of research-led companies and is the home of The BioHub. All eligible companies registering for the event will have the opportunity to win six months free laboratory space at The BioHub*, and complementary business assistance provided by the Enterprise Acceleration team at the University of Birmingham. We are looking for highly disruptive and innovative approaches, and the projects will be judged on how novel they are, as well as their long term commercial potential.